Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity

Molecular Pharmaceutics

Volumn 11, Issue 7, 2014, Pages 2305-2312

  Liu, Mei ^a   Li, Wei ^a   Larregieu, Caroline A ^b   Cheng, Meng ^a   Yan, Bihan ^a   Chu, Ting ^a   Li, Hui ^c,d   Mao, Sheng Jun ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

acute myeloid leukemia (AML); daunorubicin; drug targeting; liposome; low density lipoprotein receptor (LDLR)

Indexed keywords

AA13 PEPTIDE; DAUNORUBICIN; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-METHOXY-POLY(ETHYLENE GLYCOL 2000); ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; MALEIMIDE; MALEIMIDE DERIVATIVE; PEPTIDE; PHOSPHATIDYLETHANOLAMINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CYTOTOXICITY; DRUG ACCUMULATION; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SYNTHESIS; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; LEUKEMIA, MYELOID, ACUTE; MEDICINAL CHEMISTRY; METABOLISM; NUDE MOUSE; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DAUNORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIPOSOMES; MALEIMIDES; MICE; MICE, NUDE; PEPTIDES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RECEPTORS, LDL; TISSUE DISTRIBUTION;

EID: 84904007843     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400759d     Document Type: Article

References (39)

1. Kimby, E.; Nygren, P.; Glimelius, B. A systematic overview of chemotherapy effects in acute myeloid leukaemia Acta Oncol. 2001, 40, 231-252
2. Dores, G. M.; Devesa, S. S.; Curtis, R. E.; Linet, M. S.; Morton, L. M. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007 Blood 2012, 119, 33-34
3. Ermacora, A.; Michieli, M.; Pea, F.; Visani, G.; Bucalossi, A.; Russo, D. Liposome encapsulated daunorubicin (daunoxome) for acute leukemia Haematol. 2000, 85, 324-325
4. Slingerland, M.; Guchelaar, H. J.; Gelderbiom, H. Liposomal drug formulations in cancer therapy: 15 years along the road Drug Discovery Today 2012, 17, 160-166
5. Tardi, P.; Johnstone, S.; Harasym, N.; Xie, S.; Harasym, T.; Zisman, N. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy Leuk. Res. 2009, 33, 129-139
6. Bhattacharya, R.; Patra, C. R.; Earl, A.; Wang, S.; Katarya, A.; Lu, L. Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells Nanomed.: Nanotechnol., Biol. Med. 2007, 3, 224-238
7. Choi, C. H. J.; Alabi, C. A.; Webster, P.; Davis, M. E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 1235-1240
8. Montet, X.; Funovics, M.; Montet-Abou, K.; Weissleder, R.; Josephson, L. Multivalent effects of RGD peptides obtained by nanoparticle display J. Med. Chem. 2006, 49, 6087-6093
9. Zhou, Y.; Drummond, D. C.; Zou, H.; Hayes, M. E.; Adams, G. P.; Kirpotin, D. B. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells J. Mol. Biol. 2007, 371, 934-947
10. Bross, P. F.; Beitz, J.; Chen, G.; Chen, X. H.; Duffy, E.; Kieffer, L. Approval summary: Gemtuzumab Ozogamicin in relapsed acute myeloid leukemia Clin. Cancer Res. 2001, 7, 1490-1496
11. Petersdorf, S. H.; Kopecky, K. J.; Slovak, M.; Willman, C.; Nevill, T.; Brandwein, J. A phase 3 study of Gemtuzumab Ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia Blood 2013, 121, 4854-4860
12. Jensen, M. K. No evidence of survival benefit with addition of Gemtuzumab Ozogamicin to standard medical research council induction chemotherapy J. Clin. Oncol. 2013, 31, 1700
13. Castaigne, S. Why is it so difficult to use Gemtuzumab Ozogamicin? Blood 2013, 121, 4813-4814
14. Rowe, J. M.; Löwenberg, B. Gemtuzumab Ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug Blood 2013, 121, 4838-4841
15. OHear, C.; Inaba, H.; Pounds, S.; Shi, L.; Dahl, G.; Bowman, W. P. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia Cancer 2013, 119, 4036-4043
16. Tatidis, L.; Masquelier, M.; Vitols, S. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines Biochem. Pharmacol. 2002, 63, 2169-2180
17. Vitols, S.; Angelin, B.; Ericsson, S.; Gahrton, G.; Juliusson, G.; Masquelier, M. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 2598-2602
18. Vitols, S.; Norgren, S.; Juliusson, G.; Tatidis, L.; Luthman, H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells Blood 1994, 84, 2689-2698
19. Ho, Y.; Smith, R. G.; Brown, M. S.; Goldstein, J. L. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells Blood 1978, 52, 1099-1114
20. Vitols, S.; Gahrton, G.; Ost, A.; Peterson, C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation Blood 1984, 63, 1186-1193
21. Frostegård, J.; Hamsten, A.; Gidlund, M.; Nilsson, J. Low density lipoprotein-induced growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein J. Lipid Res. 1990, 31, 37-44
22. Gorfien, S.; Paul, B.; Walowitz, J.; Keem, R.; Biddle, W.; Jayme, D. Growth of NS0 cells in protein-free, chemically defined medium Biotechnol. Prog. 2000, 16, 682-687
23. Borén, J.; Lee, I.; Zhu, W.; Arnold, K.; Taylor, S.; Innerarity, T. L. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100 J. Clin. Invest. 1998, 101, 1084
24. Segrest, J. P.; Jones, M. K.; De Loof, H.; Dashti, N. Structure of apolipoprotein B-100 in low density lipoproteins J. Lipid Res. 2001, 42, 1346-1367
25. Baillie, G.; Owens, M.; Halbert, G. A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro J. Lipid Res. 2002, 43, 69-73
26. Hayavi, S.; Halbert, G. W. Synthetic low-density lipoprotein, a novel biomimetic lipid supplement for serum-free tissue culture Biotechnol. Prog. 2005, 21, 1262-1268
27. Nikanjam, M.; Gibbs, A. R.; Hunt, C. A.; Budinger, T. F.; Forte, T. M. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme Int. J. Pharm. 2007, 328, 86-94
28. Nikanjam, M.; Gibbs, A. R.; Hunt, C. A.; Budinger, T. F.; Forte, T. M. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme J. Controlled Release 2007, 124, 163-171
29. Lehtinen, J.; Magarkar, A.; Stepniewski, M.; Hakola, S.; Bergman, M.; Róg, T. Analysis of cause of failure of new targeting peptide in PEGylated liposome: molecular modeling as rational design tool for nanomedicine Eur. J. Pharm. Sci. 2012, 46, 121-130
30. Santoso, B.; Lam, S.; Murray, B. W.; Chen, G. A simple and efficient maleimide-based approach for peptide extension with a cysteine-containing peptide phage library Bioorg. Med. Chem. Lett. 2013, 23, 5680-5683
31. Callens, C.; Coulon, S.; Naudin, J.; Radford-Weiss, I.; Boissel, N.; Raffoux, E. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia J. Exp. Med. 2010, 207, 731-750
32. McCormack, E.; Mujić, M.; Osdal, T.; Bruserud, Ø.; Gjertsen, B. T. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia Blood 2013, 121, 34-42
33. Ichihara, T.; Akada, J. K.; Kamei, S.; Ohshiro, S.; Sato, D.; Fujimoto, M. A novel approach of protein immobilization for protein chips using an oligo-cysteine tag Int. J. Protein Res. 2006, 5, 2144-2151
34. Gubernator, J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity Expert Opin. Drug Delivery 2011, 8, 565-580
35. Goldstein, J. L.; Brown, M. S.; Anderson, R. G. W.; Russell, D. W.; Schneider, W. J. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system Annu. Rev. Cell Biol. 1985, 1, 1-39
36. Sainte-Marie, J.; Vidal, M.; Sune, A.; Ravel, S.; Philippot, J. R.; Bienvenue, A. Modification of LDL-receptor-mediated endocytosis rates in CEM lymphoblastic cells grown in lipoprotein-depleted fatal calf serum Biochim. Biophys. Acta 1989, 982, 265-270
37. Young, T. K.; Falcao, C.; Torchilin, V. P. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)2 and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy Mol. Pharmaceutics 2009, 6, 971-977
38. Gu, F.; Zhang, L. F.; Teply, B. A.; Mann, N.; Wang, A.; Radovic-Moreno, A. F. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2586-2591
39. Shahin, M.; Soudy, R.; Aliabadi, H. M.; Kneteman, N.; Kaur, K.; Lavasanifar, A. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity Biomaterials 2013, 34, 4089-4097